This website uses cookies

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will only use cookies based on your decision.

FDG PET/CT and breast cancer

By Kristin Schmiedehausen, MD|01/01/2015

Breast cancer is the most common cause of cancer death in women.1 PET/CT using Fludeoxyglucose F18 injection (18F FDG) can impact staging and restaging of breast cancer, especially in patients with inflammatory, locally advanced and metastatic breast cancer. Download the white paper to learn about the increasing role PET/CT has in breast cancer in addition to breast cancer treatment guidelines and reimbursement options for certain countries.

1
Subscription Button Icon
Be the first to know about our events, training, and news